DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages


UVA1 phototherapy

Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand. 2012.


What is UVA1?

The term phototherapy or light therapy applies to exposure of the skin to specific wavelengths of light or electromagnetic radiation. There are three ranges of radiation that are applied in phototherapy: infrared (800-3000 nm), visible light (400-800 nm), and ultraviolet radiation (100-400 nm). Treatment of skin disorders most often involves ultraviolet radiation (UVR).

UVA1 is the name given to the waveband of electromagnetic radiation ranging from 340-400nm. UVA1 phototherapy filters out lower wavelengths. It is effective in clearing or controlling a variety of skin diseases.

How does UVA1 help skin diseases?

UVA1 is thought to be effective in treating skin disease by suppressing components of cell-mediated immune function.

UVA1 penetrates deep into the reticular layer of the dermis, acting on fibroblasts, dendritic cells and inflammatory cells, particularly T-cell lymphocytes, as well as mast cells and granulocytes.

UVA1 radiation induces apoptosis (cell death) in the presence of active oxygen molecules, such as singlet oxygen, hydrogen peroxide, or superoxide radicals. It activates programmed (induced) and non-programmed (natural) cell death.

The success of UVA1 in atopic dermatitis was found to result from UVA radiation-induced apoptosis in skin-infiltrating T-helper cells, leading to the loss of T cells from eczematous skin. The effect of UVA1 in inducing T lymphocyte apoptosis may also help treat cutaneous T cell lymphoma (CTCL).

UVA1 also activates fibroblasts to produce matrix metalloproteinases, which break down excess collagen in the extracellular matrix.  is why it is useful in sclerosing (scar-like) skin conditions.

What are the indications for UVA1?

UVA1 radiation can be used to treat the following skin diseases:

High-dose UVA1 has also been observed to help:

What is the dose regimen for UVA1?

UVA1 treatment units typically consist of metal halide lamps equipped with special optical filters. Smaller cabinets provide localised therapy, whereas whole-body treatment can be carried out using lie-down or standing UVA1 cabinets.

In North America UVA1 availability is limited, perhaps due to the relatively high equipment costs; UVA1 units are usually two to three times more expensive than conventional whole body narrowband UV treatment units. There are to date no UVA1 units in New Zealand (November 2012). Conventional UVA produced by UV machines in NZ contains about 80% of UVA1. The main difficulty with older machines is the time taken to reach adequate doses of UVA1 so that only a low-dose regimen is practicable.

There are three dosing regimens for UVA1.

  • Low dose UVA1 refers to 10-20 J/cm2 per single dose.
  • Medium dose UVA1 refers to 50-60 J/cm2 per single dose.
  • High dose UVA1 refers to 130 J/cm2 per single dose.

The long-term risks of high dose UVA1 are uncertain, so no more than 10-15 treatments per cycle and two cycles per year are recommended.

If there is a history of photosensitivity, the patient may undergo phototesting to screen for unusual UVA1 reactivity (e.g., polymorphous light eruption or chronic actinic dermatitis).

UVA1 treatment is performed five times a week, usually for 3-4 weeks. However, there are no strict guidelines for its use, and therefore the dose and number of irradiations can be adjusted to each patient individually, taking into account their different skin phototypes and skin problem.

Indication Strength of evidence Recommended dosing regimen Number of exposures
Atopic dermatitis Randomised controlled trials Medium-dose 15
Sclerosing skin diseases Randomised controlled trials Medium- and/or high-dose 20-40
T-cell lymphoma Open studies Medium- and/or high-dose 10-35
Urticaria pigmentosa Open studies Medium- and/or high-dose 10-15

Continued improvement may occur for up to several months after a treatment course. Maintenance phototherapy is not routinely recommended. As the long-term side-effects of UVA1 are unknown, patients younger than 18 years of age, should be treated cautiously.

What are the adverse effects of UVA1?

Adverse effects with UVA1 phototherapy have been classified as acute (short-term) or chronic (long-term).

Acute side effects of UVA1 phototherapy are:

Chronic side-effects of UVA1 phototherapy include:

What are the contraindications to UVA1 therapy?

UVA1 should not be used for patients that have photosensitivity disorders, particularly:

Relative contraindications include:


UVA1 is a form of phototherapy that appears useful for treating atopic dermatitis and sclerotic skin diseases (scleroderma). Overall, the side-effects are well tolerated. The long-term adverse effects and effectiveness in other skin diseases remain uncertain.



  • Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001 Oct; 45(4):503–7. PubMed
  • Andres C, Kollmar A, Mempel M, et al. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010;162(2):445–7. PubMed
  • Morita A, Kobayashi K, Isomura I, et al. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000 Oct; 43(4):670–4. PubMed
  • Stege H, Megahed M, et al. Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999 Jul; 41(1):47–50. PubMed
  • Suh KS, Kang JS, Baek JW, et al. Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases. Ann Dermatol 2010 Feb; 22(1):1–8. PubMed
  • Stege H, Schopf E, Ruzicka T, et al. High-dose UVA1 for urticaria pigmentosa. Lancet 1996 Jan 6; 347(8993):64. PubMed
  • Gobello T, Mazzanti C, Sordi D, et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol 2003 Oct; 49(4):679–84. PubMed
  • York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol 2010 Jun; 49(6):623–30. PubMed
  • Tuchida C, Lim H, et al. Comparison of broadband UVB, narrowband UVB, broadband UVA and UVA1 on activation of apoptotic pathways in human peripheral blood mononuclear cells. Photodermatol Photoimmunol Photomed 2007;23:2–9. Journal

On DermNet

Other websites

Books about skin diseases


Related information

Sign up to the newsletter